Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production

@article{Gauvreau2014TargetingMI,
  title={Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production},
  author={Gail M. Gauvreau and Jeffrey M Harris and Louis-Philippe Boulet and Heleen Scheerens and J Mark FitzGerald and Wendy S. Putnam and Donald W. Cockcroft and Beth E. Davis and Richard D Leigh and Yanan Zheng and Barbro Dahl{\'e}n and Yehong Wang and Romeo Maciuca and Irvin Mayers and X Charlene Liao and Lawren C. Wu and John G. Matthews and Paul M. O'Byrne},
  journal={Science Translational Medicine},
  year={2014},
  volume={6},
  pages={243ra85 - 243ra85}
}
A humanized monoclonal antibody that targets the membrane IgE B cell receptor was associated with improvements in asthmatic airway responses. Asthma Antibody Clears the Air A humanized antibody may be the key for treating allergic asthma. Gauvreau et al. report that quilizumab—a humanized monoclonal antibody that targets the membrane immunoglobulin E (IgE) B cell receptor—led to reductions in total and allergen-specific serum IgE that were sustained for 6 months after dosing and were associated… Expand
Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells
TLDR
High-affinity anti-IgE antibodies (MEDI4212) are generated that have the potential to both neutralize soluble IgE and eliminate IgE-expressing B-cells through antibody-dependent cell-mediated cytotoxicity and to provide increased long-term benefit by eliminating the IgE expressing B cells before they differentiate and become IgE secreting plasma cells. Expand
Quantitative in vitro and in vivo models to assess human IgE B cell receptor crosslinking by IgE and EMPD IgE targeting antibodies.
TLDR
A readily quantifiable cell model was developed that allows for in vivo validation of antibodies addressing human EMPD IgE, and provides the means for quantitative assessment of IgE BCR crosslinking activity which is increasingly gaining attention with respect to forthcoming second generation anti-IgE clinical candidates such as Ligelizumab or other clinical candidates featuring additional effector functions such as IgE bCR cross linking activity. Expand
Treating IgE‐mediated diseases via targeting IgE‐expressing B cells using an anti‐CεmX antibody
  • S. Liour, Andrew Tom, Y. Chan, T. Chang
  • Medicine
  • Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
  • 2016
TLDR
These unique pharmacologic mechanisms potentially enable anti‐CεmX to provide different clinical utilities from anti‐IgE and serve as a therapeutic and a prophylactic in some IgE‐mediated diseases, which are not adequately treated with current medicine. Expand
Generation of IgE-specific cytotoxic T lymphocytes as a novel immunotherapeutic approach for the treatment of allergic asthma.
TLDR
IgE-specific CTLs generated ex vivo may provide a novel treatment for allergic asthma and lead to a new therapy for other immunological disorders. Expand
Targeting IgE production in mice and humans.
TLDR
Clinical studies indicate that, similar to mice, a proportion of IgE in humans is derived from ongoing IgE immune responses and short-lived plasma cells, which may lead to new therapies for the treatment of allergic diseases. Expand
Tracing IgE-Producing Cells in Allergic Patients
TLDR
Current knowledge and unanswered questions regarding IgE production in allergic patients as well as possible therapeutic approaches targeting IgE are discussed. Expand
Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE+ B cells
TLDR
An overview of the current state of IgE targeted therapy development is provided, focusing on three areas of translational research: IgE neutralization in blood; IgE-effector cell elimination; and IgE+ B cell reduction. Expand
Development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies
TLDR
The discovery strategy, preclinical and early clinical development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies and evidence of human efficacy and safety of this new therapeutic strategy are still lacking. Expand
Tuning IgE: IgE-Associating Molecules and Their Effects on IgE-Dependent Mast Cell Reactions
TLDR
The mechanistic basis for how IgE-dependent mast cell activation is regulated by the IgE -associating molecules, including the newly developed therapeutic candidates, are discussed. Expand
Biology and dynamics of B cells in the context of IgE‐mediated food allergy
TLDR
An overview of the current knowledge on the biology of B cells in relation to IgE‐mediated food allergies is provided and where in the body IgE class switch recombination of food allergen‐specific B cells occurs is still not fully understood. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 73 REFERENCES
Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice.
TLDR
Targeting of human IgE-producing B cells with apoptosis-inducing M1'-specific antibodies may be a novel treatment for asthma and allergy. Expand
Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody.
TLDR
XmAb7195 acts by IgE sequestration coupled with an FcγRIIb-mediated inhibitory mechanism to suppress the formation of IgE-secreting plasma cells and reduce both free and total IgE levels. Expand
Quilizumab is an Afucosylated Humanized Anti-M1 Prime Therapeutic Antibody
TLDR
Targeting of the immunoglobulin E (IgE) using a humanized monoclonal antibody that binds and neutralizes free serum IgE results in a reduction in exacerbations, decreases in symptom scores and the use of rescue medications, and provements in quality of life in moderate-to-severe allergic asthmatics who remain symptomatic despite theUse of high-dose ICS and long-acting medications. Expand
Targeting the Extracellular Membrane-Proximal Domain of Membrane-Bound IgE by Passive Immunization Blocks IgE Synthesis In Vivo1
TLDR
The present work raised a mouse mAb directed exclusively against the extracellular membrane-proximal domain of mIgE and induced receptor-mediated apoptosis in vitro, leading to a decrease of allergen-specific serum IgE levels. Expand
The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects.
TLDR
It is concluded that an anti-IgE monoclonal antibody, which inhibits binding of IgE to its receptor, suppresses the early- and late-phase responses to inhaled allergen in allergic asthmatic subjects. Expand
Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.
TLDR
A pharmacokinetic-pharmacodynamic model incorporating omalizumab-IgE binding and feedback for control of IgE production indicates that omalIZumab reduces production of IgN, raising the possibility that indefinite treatment may not be required, only for perhaps a few years. Expand
Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response.
TLDR
The inhibitory effects of rhuMAb-E25 on allergen-induced EAR suggest that it may be an effective, novel antiallergic treatment for asthma. Expand
The biology of IGE and the basis of allergic disease.
TLDR
There is now compelling evidence that the microenvironment of mucosal tissues of allergic disease favors class switching to IgE; and the exceptionally high affinity of IgE for FcepsilonRI can now be interpreted in terms of the recently determined crystal structures of IgG-FcgammaR complexes. Expand
Unique Epitopes on CεmX in IgE–B Cell Receptors Are Potentially Applicable for Targeting IgE-Committed B Cells
TLDR
Results suggest that 4B12 and 26H2 and an immunogen using the peptide segments recognized by these mAbs are potentially useful for targeting mIgE+ B cells to control IgE production. Expand
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
TLDR
The addition of omalizumab to standard asthma therapy reduces asthma exacerbations and decreases inhaled corticosteroid and rescue medication use. Expand
...
1
2
3
4
5
...